1. Home
  2. Actis

Category: life sciences

Actis eyes Indian life science labs demand with Rx Propellant deal

Global sustainable infrastructure investor Actis has bought Rx Propellant, a platform focused on providing R&D labs and facilities to tenants in the life sciences and related sectors in India. The post Actis eyes Indian life

Apollo buys into European life science investment major Sofinnova Partners, agrees up to €1bn of fund commitments

Global buyout giant Apollo has bought a minority stake in European life sciences investment major Sofinnova Partners, as well as agreeing to commit up to €1bn to its funds. The post Apollo buys into European

Catalio Capital Management flies past Fund III goal to reach $381m final close

Life sciences investor Catalio Capital Management has soared past its target for its third flagship fundraise through a $381m final close. The post Catalio Capital Management flies past Fund III goal to reach $381m final close

Frazier Healthcare Partners soars past last life sciences fund total with new $987m fund close

Frazier Healthcare Partners has beaten its goal for its latest life sciences-focused fundraise by picking up $987m for a final close of the vehicle. The post Frazier Healthcare Partners soars past last life sciences fund

Eir Ventures picks up over €122m of investing power focused on Nordic life science sector

Nordic life science-focused venture capital house Eir Ventures has hit a €122.3m final close for its debut fundraise. The post Eir Ventures picks up over €122m of investing power focused on Nordic life science sector

Mission BioCapital more than doubles last fund total with $275m Fund V close

Specialist venture capital house Mission BioCapital has raised $275m for its fifth flagship fundraise, more than double the amount it collected for its predecessor vehicle. The post Mission BioCapital more than doubles last fund total

VC giant NEA brings in life sciences veteran Park as newest partner

Venture capital major New Enterprise Associates has brought in veteran life sciences investor Michele Park as a partner in its Menlo Park office. The post VC giant NEA brings in life sciences veteran Park as

Life science specialist Vida Ventures raises third fund in four years, brings AUM to over $1.7bn

Life sciences-focused venture capital house Vida Ventures has boosted its assets under management to more than $1.7bn in just four years through the final close of its oversubscribed third fund. The post Life science specialist

Advent Life Sciences closes pair of funds totalling $251m

Advent Life Sciences, a transatlantic venture firm focused on life science companies, has closed a pair of new funds totalling $215m.

Ex-OrbiMed Advisors execs seal $410m final close for debut Petrichor Healthcare Capital Management fund

A team of former OrbiMed Advisors investment professionals have raised $410m for the final close of their debut Petrichor Healthcare Capital Management fund.

TVM Capital Life Science closes its new fund on $478m

TVM Capital Life Science has held the $478m final close of its second Innovation fund, which will back life science companies in North America and Europe.

Sofinnova Partners swoops for Anderson as partner to boost growth-stage Crossover Fund team

European life sciences venture capital major Sofinnova Partners has brought on board experienced former Abingworth investor Joe Anderson as a partner.

Aisling Capital rounds up more than $144m towards latest flagship life science fundraise

Life sciences-focused private equity house Aisling Capital has raised more than $144m towards its latest flagship fundraise.

Sofinnova Partners sells its stake in Corvidia in $2.1bn deal

Life sciences venture capital firm Sofinnova Partners has sold its portfolio company Corvidia Therapeutics to Novo Nordisk for $2.1bn.

We use cookies to offer you a better browsing experience. If you continue to use this site, you consent to our use of cookies.
We use cookies to offer you a better browsing experience. If you continue to use this site, you consent to our use of cookies.